<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="lymphovista-mrd-mattlener-pf1319">
    <meta name="study:title" content="PF1319 - LYMPHOVISTA - A validated platform for genotyping and MRD assessment in different types of lymphoma">
    <meta name="study:fileName" content="Abstracts/LYMPHOVISTA-MRD-MATTLENER-PF1319.html">
    <meta name="study:cancerTypes" content="FL,MZL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="Not Specified">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="">

    <title>PF1319: LYMPHOVISTA - Genotyping and MRD Assessment in Lymphoma (Mattlener) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF1319 - LYMPHOVISTA Platform for Genotyping & MRD Assessment</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                        <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim</h4>
                    <p>B-cell lymphomas (FL, MZL, LBCL, CNSL, HL). Aim: Validate LymphoVista ctDNA platform for genotyping & MRD.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                         <path fill-rule="evenodd" d="M11.828 2.25c-.916 0-1.699.663-1.85 1.567l-.091.549a.798.798 0 01-.517.636l-.442.177a1.875 1.875 0 00-1.905 2.403l.16.391c.162.395.046.86-.285 1.135l-.361.301a1.875 1.875 0 000 2.932l.361.301c.331.274.447.74.285 1.135l-.16.39a1.875 1.875 0 001.906 2.403l.442.177c.21.084.405.222.517.636l.091.55c.15.903.934 1.567 1.85 1.567h.344c.916 0 1.699-.663 1.85-1.567l.091-.55a.798.798 0 01.517-.636l.442-.177a1.875 1.875 0 001.905-2.403l-.16-.39c-.162-.395-.046-.86.285-1.135l.361-.301a1.875 1.875 0 000-2.932l-.361-.301c-.331-.274-.447-.74-.285-1.135l.16-.391a1.875 1.875 0 00-1.906-2.403l-.442-.177a.798.798 0 01-.517-.636l-.091-.549A1.875 1.875 0 0012.172 2.25h-.344zM12 15.75a3.75 3.75 0 100-7.5 3.75 3.75 0 000 7.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Platform (LymphoVista / LymphoVista HL)</h4>
                    <p>ctDNA sequencing. LymphoVista: 79 genes (~167kbp). LymphoVista HL: 37 genes (~83kbp).</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                         <path d="M18.375 2.25c-1.952 0-3.626 1.108-4.407 2.731a.75.75 0 00-1.336 0C11.851 3.358 10.177 2.25 8.225 2.25c-2.686 0-4.875 2.096-4.875 4.711 0 3.438 2.078 6.467 4.455 8.659a25.213 25.213 0 003.375 2.927.75.75 0 00.856.001 25.212 25.212 0 003.375-2.927C20.43 13.428 23.25 9.95 23.25 6.173c0-2.614-2.19-4.71-4.875-4.71z" /> <path fill-rule="evenodd" d="M8.25 3.75a.75.75 0 01.75.75v6a.75.75 0 01-1.5 0V4.5a.75.75 0 01.75-.75zM12 6a.75.75 0 01.75.75v3.75a.75.75 0 01-1.5 0V6.75A.75.75 0 0112 6zm2.25 2.25a.75.75 0 01.75.75v8.25a.75.75 0 01-1.5 0V9a.75.75 0 01.75-.75z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Performance (LymphoVista)</h4>
                    <p>De-novo variants: Sens. 93.6%, Spec. 99.99% (≥0.5% mAF). MRD LoD: 6.69x10<sup>-6</sup>. Clinical: Mutations in 95-100% of B-NHL.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>LymphoVista HL & Conclusion</h4>
                    <p>HL LoD: 6.54x10<sup>-6</sup>. MRD-2 neg. in HD21 assoc. w/ sig. longer PFS (HR 6.9, p<0.0001). Platform validated for B-cell lymphoma MRD.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF1319 - LYMPHOVISTA - A validated platform for genotyping and MRD assessment in different types of lymphoma</h1>
            <p class="abstract-sub-header">Julia Mattlener, Jessica Schneider, Julia K. Schleifenbaum, Sophie Heidenreich, Hodgkin Lymphoma MRD Consortium, Helen Kaul, Gundolf Schneider, Peter Borchmann, Jan-Michel Heger, Sven Borchmann</p>
            <p class="abstract-meta-info mt-2">EHA Library PF1319 | Abstract Release: 05/14/25 | Presentation: 06/13/2025</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Circulating tumor DNA (ctDNA) sequencing has advanced genotyping and minimal residual disease (MRD) assessment in lymphoma.</li>
                        <li>Current assays often lack validation and comparability.</li>
                        <li>The LymphoVista-Platform was designed and validated for ctDNA sequencing in B-cell lymphoma, compatible with small sequencing instruments for cost-effective, rapid clinical use.</li>
                        <li>LymphoVista covers diverse B-cell lymphomas, while LymphoVista HL is specialized for Hodgkin Lymphoma (HL).</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To develop an enhanced and validated ctDNA sequencing platform to facilitate de-novo variant calling and MRD assessment in lymphoma.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li><strong>LymphoVista Platform:</strong> Targets 79 genes (~167 kbp), includes modules for MRD assessment, de-novo variant calling, and validation targets.</li>
                        <li><strong>LymphoVista HL Platform:</strong> Targets 37 genes (~83 kbp), specialized for HL.</li>
                        <li><strong>Technical Validation:</strong> Performed with contrived samples (reference standard diluted in healthy donor cfDNA) to evaluate analytical performance.</li>
                        <li><strong>Clinical Samples (LymphoVista):</strong> Follicular lymphoma (FL, n=19), marginal zone lymphoma (MZL, n=6), large B-cell Lymphoma (LBCL, n=3), central nervous system lymphoma (CNSL, n=3).</li>
                        <li><strong>Clinical Validation (LymphoVista HL):</strong> Blinded study in 72 HL patients from the HD21 trial, assessing MRD after two treatment cycles (MRD-2) for prognostic value for PFS. MRD-2 positivity defined as levels above LoD.</li>
                    </ul>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Results</h2>
                    <h3 class="abstract-sub-section-title">LymphoVista Performance:</h3>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>De-novo variant detection (≥0.5% mAF): Sensitivity 93.59%, Specificity 99.99%.</li>
                        <li>MRD assessment LoD: 6.69 x 10<sup>-6</sup>, with 100% specificity, sensitivity, and accuracy for MRD levels > 3.04 x 10<sup>-5</sup>.</li>
                        <li>Clinical samples: Exonic/splicing mutations in core cancer genes (e.g., BCL2, EZH2, PIM1, TP53, IGLL5) identified in 100% of MZL, LBCL, CNSL, and 95% of FL patients.</li>
                    </ul>
                    <h3 class="abstract-sub-section-title mt-3">LymphoVista HL Performance:</h3>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>De-novo variant detection (≥0.5% mAF): Sensitivity 91.27%, Specificity 99.99%.</li>
                        <li>MRD assessment LoD: 6.54 x 10<sup>-6</sup>, with 100% specificity, sensitivity, and accuracy for MRD levels > 1.76 x 10<sup>-5</sup>.</li>
                        <li>Robust reproducibility at low MRD levels across varying operating conditions (operator, time, kit batch) for both panels.</li>
                        <li><strong>Clinical Validation (HD21 Trial, N=72 HL patients):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>MRD-2 positive: 18.5% of patients.</li>
                                <li>4-year PFS significantly longer in MRD-2 negative vs. MRD-2 positive patients: 95.3% (95% CI: 88.7-100) vs. 72.2% (95% CI: 41.5-100).</li>
                                <li>Hazard Ratio (HR) for PFS: 6.9 (95% CI: 4.5-10.6), p < 0.0001.</li>
                            </ul>
                        </li>
                    </ul>
                    <div class="chart-container my-4">
                        <img src="Assets/HD21_MRD2_PFS.jpg" alt="Kaplan-Meier curve for Progression Free Survival by MRD-2 status in HL patients from HD21 trial" class="w-full max-w-md mx-auto rounded-lg shadow-md" onerror="this.onerror=null;this.src='https://placehold.co/600x400?text=Figure+Not+Available'; this.alt='Figure placeholder: Kaplan-Meier PFS Curve for HD21 MRD-2 Status';">
                        <p class="text-xs text-center mt-1 italic">Progression Free Survival by MRD-2 status in HL patients (HD21 trial).</p>
                    </div>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>The LymphoVista platform, featuring two validated ctDNA sequencing assays, enables ultrasensitive genotyping and MRD assessment in B-cell lymphoma.</li>
                <li>Validation confirms high accuracy, specificity, sensitivity, and prognostic value of the platform.</li>
                <li>LymphoVista HL reliably predicts outcomes in HL, paving the way for MRD-guided clinical trials and clinical application.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Keywords</h2>
            <p>B cell lymphoma, Minimal residual disease (MRD), ctDNA, liquid biopsy.</p>
        </div>
        
        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>cfDNA, Cell-Free DNA; CI, Confidence Interval; CNSL, Central Nervous System Lymphoma; ctDNA, Circulating Tumor DNA; FL, Follicular Lymphoma; HL, Hodgkin Lymphoma; HR, Hazard Ratio; kbp, Kilobase Pairs; LBCL, Large B-Cell Lymphoma; LoD, Limit of Detection; mAF, Mutated Allele Frequency; MRD, Minimal Residual Disease; MRD-2, MRD after 2 treatment cycles; MZL, Marginal Zone Lymphoma; PFS, Progression-Free Survival.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Mattlener J, Schneider J, Schleifenbaum JK, et al. LYMPHOVISTA - A validated platform for genotyping and MRD assessment in different types of lymphoma. Abstract #PF1319 presented at the European Hematology Association (EHA) Congress. 13–16 June 2024, Madrid, Spain.</p>
             <p class="text-xs mt-1 italic">Note: The abstract reference is updated to EHA 2024 as per the provided abstract text. If this is for a future EHA 2025, the date and location should be updated accordingly.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA Library. Mattlener J. 06/13/2025; 4159731; PF1319 (Abstract release date: 05/14/25)</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script>
</body>
</html>